EPO and lung carcinoma: Both Concanamycin A (ConcA) and TAK-243 treatment rescued endogenous CTLA4 protein from degradation under Cycloheximide chase conditions in melanoma and lung cancer cells, whereas the proteasome inhibitor (Epo) was without effect (Fig. 1, C–F).